LIÈGE, Belgium & GRENOBLE, France, April 08, 2024 PDC line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC lung01.
PDC*line Pharma and Partners Receive €8 1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Treatment with PDC lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab PDC line Pharma, a clinical stage biotech
Preliminary results with PDC lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer